The FDA has approved ocriplasmin (Jetrea, ThromboGenics) for the treatment of symptomatic vitreomacular adhesion (VMA).
RetinAI debuts AI-powered, collaborative platform to accelerate clinical and academic research, RWE analysis in ophthalmology
Pipeline reveals bright future for combating diabetic eye disease
Genetics of glaucoma
